TGTXTG Therapeutics, Inc.

TG Therapeutics, Inc. (NASDAQ: TGTX) | Price: $58.23 | Today's Change: -2.67%

---

What Happened

TG Therapeutics filed an 8-K with the SEC on November 9, 2026, disclosing its Q2 FY2026 financial results under Items 2.02 and 9.01. The company reported revenue of $262.0 million for the quarter, alongside a net income of $5.06 million — a figure that underscores the company's continued transition toward profitability. Operating income for the period came in at $43.5 million, while basic and diluted earnings per share were $0.23 and $0.20, respectively.

---

Why It Matters

For investors, the Q2 FY2026 results represent a meaningful data point in TGTX's ongoing commercial story. Revenue of $262 million for a single quarter illustrates robust product demand — a dramatic departure from the company's earlier-stage profile, reflected in the XBRL-reported FY2022 revenue figure of just $152,000. The fact that the company is generating positive net income and operating income simultaneously indicates that revenue growth is now translating into bottom-line results, reducing the binary risk profile that has historically characterized the stock. The stock is trading at $58.23, down 2.67% on the day, which may reflect some modest disappointment or profit-taking around the release, but the fundamental picture conveyed by this filing remains constructive.

---

Analysis

The Q2 FY2026 results reinforce a commercial trajectory that has been building for several quarters. Operating income of $43.5 million against net income of $5.06 million suggests meaningful below-the-line costs — whether from interest, taxes, or other items — are compressing the net result relative to operating performance, which is worth monitoring in future disclosures. Still, positive net income is a threshold marker, and generating it at this revenue scale is significant for a company that was essentially pre-revenue as recently as FY2022.

StockWatch initiated coverage on TGTX in September 2026; this filing adds a fresh earnings data point for investors following that existing research. The gap between operating income ($43.5M) and net income ($5.1M) is a line item to watch — understanding what is absorbing that ~$38 million delta will be key to assessing how much earnings leverage the business can generate as revenue scales further. Investors should look to management's commentary in the associated earnings materials for guidance on cost structure and the trajectory of below-the-line items.

---

Disclaimer

This report is a news and informational summary based solely on data contained in TG Therapeutics' SEC filing dated November 9, 2026, and associated XBRL structured data. It does not constitute investment advice, an equity research rating, or a recommendation to buy, sell, or hold any security. Readers should conduct their own due diligence and consult a qualified financial professional before making any investment decisions.

Existing Coverage

StockWatch has full coverage on TGTX, published 2026-09-16. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-09. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1001316/000162828026071870/tgtx-20261109.htm